Relevant Literature: Amyloidosis
A small sampling of the more than 1000 articles on amyloidosis by Mayo authors
Systemic Amyloidosis (General)
Gertz MA, Dispenzieri A. Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. JAMA 2020.
Muchtar E, et al. Systemic amyloidosis from A (AA) to T (ATTR): a review. Journal of Internal Medicine. 2020.
AL Amyloidosis
Muchtar E, et al. Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update Mayo Clinic Proceedings, 2021
Grogan M, et al. Artificial Intelligence–Enhanced Electrocardiogram for the Early Detection of Cardiac Amyloidosis. Mayo Clinic Proceedings, 2021.
Sidiqi H, Gertz MA. Current Treatment Algorithm for AL Amyloidosis. Blood Cancer Journal 2021.
Heybeli C, at al. A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. Kidney International, 2021.
Dasari S et al. Amyloid Typing by Mass Spectrometry in Clinical Practice: a Comprehensive Review of 16,175 Samples. Mayo Clinic Proceedings, 2020.
Sidana S, et al. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia, 2020.
Muchtar E, at al. A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry–Verified Typing. Mayo Clinic Proceedings, 2019.
Kyle RA, et al. Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clinic Proceedings, 2019.
Zanwar S, et al. Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. Leukemia, 2019.
Abeykoon JP, et al. Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia, 2019.
Sidiqi MH, et al. Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. Journal of Clinical Oncology, 2019.
Sher T, Gertz MA. Stem cell transplantation for immunoglobulin light chain amyloidosis. Current Problems in Cancer, 2017.
Tandon N, at al. Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival. Bone Marrow Transplant, 2017.
Sidana S, et al. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. Leukemia. 2017.
Muchtar E, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017
Sher T, et al. First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis. Blood. 2016
Grogan M, et al. Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. World J Transplant. 2016
Dispenzieri A, et al. Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. Bone Marrow Transplant. 2013
Kumar S, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012
Mikhael JR, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012
Dispenzieri A, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004
Gertz MA, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005
Diagnosis of amyloidosis
Vrana JA, et al. Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica. 2014
Vrana JA, et al. Classification of amyloidosis by laser microdissection and mass spectrometry based proteomic analysis in clinical biopsy specimens. Blood. 2009
ATTR amyloidosis
Swiecicki PL, et al. Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. Amyloid. 2015
Grogan M, et al. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. Journal of the American College of Cardiology. 2016
Banerjee D, et al. Outcomes of Patients With Familial Transthyretin Amyloidosis After Liver Transplantation. Progress in Transplantation. 2017
Muchtar E, et al. Acquired transthyretin amyloidosis after domino liver transplant: Phenotypic correlation, implication of liver retransplantation. Journal of the neurological sciences. 2017
Cornwell GG, 3rd, et al. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med. 1983
Other amyloidoses
Bois MC, et al. Apolipoprotein A-IV-Associated Cardiac Amyloidosis. Journal of the American College of Cardiology. 2017
Nasr SH, et al. Novel Type of Renal Amyloidosis Derived from Apolipoprotein-CII. J Am Soc Nephrol. 2017
LOCALIZED AMYLOIDOSIS
Kourelis TV et al. Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience. Mayo Clinic Proceedings, 2017.
